Drugs / BCG SII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT02380508 | Feb 2015 → Nov 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04351685 Comparator | Nov 2020 → Oct 2024 | tuberculosis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG SII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04351685 ↗ |
| Known as | Bacille Calmette-Guérin Serum Institute of India | “Bacille Calmette-Guérin Serum Institute of India” NCT02380508 ↗ |
| Modality | Vaccine | “Bacille Calmette-Guérin (BCG), the only currently licenced tuberculosis vaccine” PMID 35552463 ↗ May 2022 |
| Route | Other | “administered intradermally” NCT04351685 ↗ |